Sinovac Life Sciences Co., Ltd.

This early-stage trial tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 180 healthy infants and toddlers will receive either the new vaccine or an …

This study tests a new vaccine (PCV24) that protects against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. About 420 healthy children aged 2 months to 5 years will receive either the new vaccine or an existing one to compare …

This study tests a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine safely triggers a strong immune response against 13 types of pneumococcal bacteria, which can cause seriou…